Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Impact of COVID-19 Disruptions on Global BCG Coverage and Paediatric TB Mortality: A Modelling Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies

    Research output: Contribution to journalReviewResearchpeer-review

  3. The role of Plasmodium falciparum variant surface antigens in protective immunity and vaccine development

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Characterization of a Novel Hepatitis C Virus Genotype 1 Subtype from a Patient Failing 4 Weeks of Glecaprevir-Pibrentasvir Treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Targeting the Pentose Phosphate Pathway for SARS-CoV-2 Therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has demonstrated the value of pursuing different vaccine strategies. Vaccines based on whole viruses, a widely used vaccine technology, depend on efficient virus production. This study aimed to establish SARS-CoV-2 production in the scalable packed-bed CelCradleTM 500-AP bioreactor. CelCradleTM 500-AP bottles with 0.5 L working volume and 5.5 g BioNOC™ II carriers were seeded with 1.5 × 108 Vero (WHO) cells, approved for vaccine production, in animal component-free medium and infected at a multiplicity of infection of 0.006 at a total cell number of 2.2-2.5 × 109 cells/bottle seven days post cell seeding. Among several tested conditions, two harvests per day and a virus production temperature of 33 °C resulted in the highest virus yield with a peak SARS-CoV-2 infectivity titer of 7.3 log10 50% tissue culture infectious dose (TCID50)/mL at 72 h post-infection. Six harvests had titers of ≥6.5 log10 TCID50/mL, and a total of 10.5 log10 TCID50 were produced in ~5 L. While trypsin was reported to enhance virus spread in cell culture, addition of 0.5% recombinant trypsin after infection did not improve virus yields. Overall, we demonstrated successful animal component-free production of SARS-CoV-2 in well-characterized Vero (WHO) cells in a scalable packed-bed bioreactor.

Original languageEnglish
Article number706
JournalVaccines
Volume9
Issue number7
ISSN2076-393X
DOIs
Publication statusPublished - 29 Jun 2021

    Research areas

  • Animal component-free, CelCradle, COVID-19, Inactivated vaccine, Packed-bed, Scalable bioreactor, Severe acute respiratory syndrome coronavirus 2, Vero cells, Whole virus vaccine

ID: 66572975